UBS Group Increases Insmed (NASDAQ:INSM) Price Target to $110.00

Insmed (NASDAQ:INSM) had its price objective increased by UBS Group from $105.00 to $110.00 in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on INSM. JPMorgan Chase & Co. increased their target price on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Royal Bank of Canada assumed coverage on shares of Insmed in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $100.00 price target on the stock. Wells Fargo & Company raised their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Morgan Stanley raised their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and a consensus price target of $93.33.

Insmed Trading Down 3.3 %

Shares of INSM opened at $75.02 on Thursday. Insmed has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a market cap of $13.58 billion, a P/E ratio of -13.42 and a beta of 1.11. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company’s fifty day simple moving average is $75.55 and its 200-day simple moving average is $73.85.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. As a group, analysts expect that Insmed will post -4.56 EPS for the current year.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 3,344 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total value of $220,403.04. Following the sale, the insider now directly owns 102,766 shares in the company, valued at approximately $6,773,307.06. This trade represents a 3.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 2,978 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.36, for a total transaction of $188,686.08. Following the completion of the sale, the chief executive officer now owns 392,589 shares in the company, valued at $24,874,439.04. This represents a 0.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock worth $42,859,028 in the last three months. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of Insmed

A number of institutional investors have recently modified their holdings of INSM. Darwin Global Management Ltd. boosted its holdings in shares of Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock valued at $894,796,000 after buying an additional 2,463,261 shares in the last quarter. Norges Bank acquired a new stake in Insmed in the 4th quarter worth approximately $126,606,000. Vanguard Group Inc. boosted its stake in Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares in the last quarter. Vestal Point Capital LP boosted its stake in Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after purchasing an additional 850,000 shares in the last quarter. Finally, Brown Advisory Inc. acquired a new stake in Insmed in the 4th quarter worth approximately $45,773,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.